Form 4: BridgeBio Pharma CFO Brian Stephenson Reports Stock Transactions
SEC Form 4 Filing
Brian Stephenson, CFO of BridgeBio Pharma, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- Brian Stephenson, the Secretary, Treasurer, and CFO of BridgeBio Pharma, filed a Form 4 detailing changes in beneficial ownership.
- On February 16, 2025, Stephenson acquired 25,798 shares of common stock through the vesting of restricted stock units (RSUs).
- On the same day, 13,102 shares were withheld by the issuer to cover Stephenson's tax obligations related to the RSU vesting.
- Stephenson also sold 4,148 shares of common stock on February 19, 2025, at a weighted average price of $36.1556 per share, pursuant to a Rule 10b5-1 sales plan.
- Following these transactions, Stephenson directly owns 102,464 shares of BridgeBio Pharma common stock and holds various tranches of RSUs with differing vesting schedules.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing primarily reflects routine transactions related to executive compensation and a pre-planned stock sale. There is no indication of unusual or concerning activity.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to gauge management's sentiment and confidence in the company's prospects.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in the financial industry.
- Comparing the trading activity of BridgeBio Pharma's executives with those of similar biotech companies like Amgen or Vertex Pharmaceuticals can provide insights into relative valuation and sentiment.
- The use of 10b5-1 plans is a standard method for insiders to sell shares while avoiding accusations of trading on non-public information, similar to practices seen at companies like Regeneron and Gilead Sciences.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by increasing the number of shares outstanding due to RSU vesting and potentially affecting the stock price due to the sale of shares.
Key Dates
| Date | Description |
|---|---|
| 03/22/2024 | Rule 10b5-1 sales plan adopted by the Reporting Person |
| 05/16/2021 | Initial vesting date for one tranche of RSUs |
| 11/16/2022 | Initial vesting date for one tranche of RSUs |
| 05/16/2023 | Initial vesting date for one tranche of RSUs |
| 05/16/2024 | Initial vesting date for one tranche of RSUs |
| 02/14/2025 | Acquisition of 158 shares through Employee Stock Purchase Plan |
| 02/16/2025 | Vesting of RSUs and acquisition of 25,798 shares; withholding of 13,102 shares for taxes |
| 02/19/2025 | Sale of 4,148 shares at an average price of $36.1556 |
Keywords
Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, BridgeBio Pharma, Stephenson, BBIO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.